晨光生物科技集团股份有限公司 2020 年第三季度报告全文 晨光生物科技集团股份有限公司 2020 年第三季度报告 2020-146 2020 年 10 月 1 晨光生物科技集团股份有限公司 2020 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人卢庆国、主管会计工作负责人周静及会计机构负责人(会计主管 人员)宋书军声明：保证季度报告中财务报表的真实、准确、完整。 2 晨光生物科技集团股份有限公司 2020 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | --- | --- | --- | --- | --- | --- | --- | --- | --- | |-------|--------|-----------------------------------------------------|-------|----- ...

晨光生物科技集团股份有限公司 2020 年半年度报告全文 晨光生物科技集团股份有限公司 2020 年半年度报告 2020-108 2020 年 08 月 1 晨光生物科技集团股份有限公司 2020 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别 和连带的法律责任。 公司负责人卢庆国、主管会计工作负责人周静及会计机构负责人(会计主管 人员)宋书军声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本报告涉及未来计划等前瞻性陈述，不构成公司对投资者的实质承诺，投 资者及相关人士应当对此保持足够的风险认识，并且应当理解计划、预测与承 诺之间的差异。 公司在本报告第四节"经营情况讨论与分析"中"九、公司面临的风险和应对 措施"中详细描述了公司可能面临的风险及应对措施，敬请投资者特别关注相关 内容，注意投资风险。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 晨光生物科技集团股份有限公司 2020 年半年度报告全文 目 录 | ...

晨光生物科技集团股份有限公司 2020 年第一季度报告全文 晨光生物科技集团股份有限公司 2020 年第一季度报告 2020-055 2020 年 04 月 1 晨光生物科技集团股份有限公司 2020 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人卢庆国、主管会计工作负责人周静及会计机构负责人(会计主管 人员)宋书军声明：保证季度报告中财务报表的真实、准确、完整。 2 晨光生物科技集团股份有限公司 2020 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | |-----------------------------------------------------|------------------|------------------|---------------------------| | ...

Financial Performance - The total revenue for 2019 was CNY 3,265,232,815.43, representing a 6.59% increase from CNY 3,063,440,575.35 in 2018[17]. - The net profit attributable to shareholders for 2019 was CNY 193,572,517.02, a 33.24% increase compared to CNY 145,283,057.15 in 2018[17]. - The net profit after deducting non-recurring gains and losses was CNY 178,488,174.16, up 47.25% from CNY 121,216,504.02 in 2018[17]. - The basic earnings per share for 2019 was CNY 0.3769, an increase of 33.04% from CNY 0.2833 in 2018[17]. - The total assets at the end of 2019 were CNY 4,507,082,722.33, a 34.25% increase from CNY 3,357,108,727.95 at the end of 2018[17]. - The net assets attributable to shareholders at the end of 2019 were CNY 1,748,100,417.02, a slight increase of 0.23% from CNY 1,744,120,502.21 at the end of 2018[17]. - The net cash flow from operating activities for 2019 was CNY -24,346,095.32, an improvement of 56.67% from CNY -56,182,968.88 in 2018[17]. - The weighted average return on equity for 2019 was 10.65%, up from 8.63% in 2018[17]. - The company reported a quarterly revenue of CNY 959,104,617.63 in Q4 2019, which was the highest among the four quarters[19]. Dividend Distribution - The profit distribution plan approved by the board proposes a cash dividend of 0.5 RMB per 10 shares, based on a total of 481,561,019 shares[4]. - The company distributed a cash dividend of 0.5 yuan per 10 shares, totaling 24,078,050.95 yuan for the year 2019[147]. - The total cash dividend, including other methods, amounted to 171,545,884.66 yuan, representing 100% of the total distributable profit[148]. - The cash dividend for 2019 accounted for 12.44% of the consolidated net profit attributable to shareholders[151]. - Over the past three years, the company has maintained a cash dividend distribution policy, with a minimum of 10% of the distributable profit allocated for cash dividends annually[145]. International Operations and Risks - The company aims to build a global natural extract industry base, with significant reliance on overseas revenue, which constitutes a large portion of total revenue[4]. - The company acknowledges potential risks from varying legal, tax, and foreign exchange regulations in different countries, which could adversely affect performance[4]. - The company’s overseas income is primarily settled in USD, making it sensitive to currency fluctuations[4]. - Future export volumes are expected to grow as production scales up, but may be impacted by changes in foreign exchange policies[4]. - The company emphasizes the importance of thorough research before project investments to minimize risks associated with overseas operations[4]. - The company is exposed to exchange rate fluctuations due to a significant portion of its revenue being generated from overseas sales, primarily settled in USD[140]. - The company benefits from export tax rebate policies, which enhance its competitiveness in international markets, but any changes in these policies could impact operational costs[141]. Research and Development - The company is focused on R&D with a market-oriented approach, implementing a phased development model for new products[29]. - The company has established 21 technology platforms, including 5 national-level platforms and 12 provincial-level platforms, contributing to a total of 60 technology-related awards received[38]. - The company has applied for 324 patents, with 206 patents granted, and has published 128 papers, showcasing its strong focus on research and development[40]. - The company has developed new products such as green coffee bean extract and pepper oil resin, enhancing its product portfolio to meet market demands[37]. - The company invested CNY 184,718,776.76 in R&D in 2019, representing 5.66% of its operating revenue[84]. - The number of R&D personnel increased to 117 in 2019, accounting for 8.74% of the total workforce[84]. Production and Supply Chain - The company is expanding its raw material bases in regions like Xinjiang, India, and Yunnan, and is trial planting in Zambia[29]. - The company has established a stable supply chain by collaborating with local farmers and agricultural institutions in regions like Xinjiang and Yunnan, ensuring a steady supply of high-quality raw materials[46]. - The company has developed a unique "three-in-one" planting model in collaboration with seed companies to ensure stable raw material supply[46]. - The company has successfully commercialized high-purity, application-oriented products, breaking foreign monopolies in the high-end application market[37]. - The company has implemented a cost control system that significantly reduces raw material procurement costs and improves production efficiency[47]. Market Position and Sales - The company’s major products include natural pigments and extracts, with key products like chili red pigment and lutein leading the industry[27]. - In 2019, the company achieved a sales volume of 5,896 tons of chili red pigment, maintaining its position as the world's number one for twelve consecutive years[52]. - The sales volume of feed-grade lutein reached 385 million grams, representing a year-on-year growth of approximately 18%[52]. - The sales volume of food-grade lutein increased by about 62% to 43.67 million grams[53]. - The company expanded its planting of marigold in Xinjiang to over 150,000 acres and in Yunnan to nearly 40,000 acres, contributing to local farmers' income and government support[53]. Financial Management and Investments - The company has not identified any new significant risks that could adversely affect operations in the next reporting period[4]. - The company has established a management system for raised funds to protect investor rights and ensure proper usage[105]. - The company has committed to not engage in any business that directly or indirectly competes with its main operations, ensuring no similar products are produced[152]. - The company has a clear and transparent profit distribution policy, ensuring that minority shareholders have the opportunity to express their opinions[146]. - The company has not faced any major litigation or arbitration matters during the reporting period[165]. Environmental and Social Responsibility - The company is actively investing in environmental protection facilities and has implemented a strict environmental monitoring system to comply with increasing regulatory standards[140]. - The company has implemented a clean production system with wastewater and waste gas recycling, achieving compliance with environmental standards[190]. - The company donated approximately CNY 100,000 to local education and public welfare initiatives during the reporting period[188]. Corporate Governance - The board of directors has confirmed the accuracy and completeness of the annual report, ensuring no misleading statements or omissions[3]. - The company has established a safety management department and emphasizes regular maintenance of production equipment to ensure safety[187]. - The company has maintained a continuous relationship with its auditing firm for 7 years, with an audit fee of RMB 826,000[164].

晨光生物科技集团股份有限公司 2019 年第三季度报告全文 晨光生物科技集团股份有限公司 2019 年第三季度报告 2019-171 2019 年 10 月 1 晨光生物科技集团股份有限公司 2019 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人卢庆国、主管会计工作负责人周静及会计机构负责人(会计主管 人员)宋书军声明：保证季度报告中财务报表的真实、准确、完整。 2 晨光生物科技集团股份有限公司 2019 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | --- | |-----------------------------------------------------|------------------|-------------------------|----------------- ...

Financial Performance - The company reported a significant increase in revenue, with total operating income reaching RMB 1.5 billion, representing a year-on-year growth of 25%[5]. - Total revenue for the reporting period reached ¥1,610,469,899.53, an increase of 24.27% compared to ¥1,295,956,241.87 in the same period last year[23]. - Net profit attributable to shareholders was ¥111,025,496.29, up 17.38% from ¥94,588,768.77 year-on-year[23]. - Basic earnings per share increased by 22.22% to ¥0.22, compared to ¥0.18 in the same period last year[23]. - The company's operating revenue for the reporting period reached RMB 1,610,469,899.53, representing a year-on-year increase of 24.27% compared to RMB 1,295,956,241.87 in the same period last year[69]. - The gross profit margin for the natural colorants/spices/nutrition and medicinal products segment increased, with revenue of RMB 825,206,000 and a gross profit of RMB 180,970,100, reflecting year-on-year growth of 37% and 27% respectively[71]. - The net profit for the first half of 2019 was CNY 108,847,705.09, representing a 16.7% increase from CNY 93,304,480.91 in the first half of 2018[188]. - The total comprehensive income for the first half of 2019 was CNY 111,386,001.00, compared to CNY 86,898,275.10 in the same period of 2018, reflecting a growth of 28.0%[189]. Cash Flow and Financial Position - Net cash flow from operating activities surged by 159.16% to ¥429,174,323.95, compared to ¥165,600,957.26 in the previous year[23]. - Cash and cash equivalents increased by 61.78%, mainly due to the accumulation of unused funds from guarantees and temporary receivables[36]. - The company's total liabilities decreased to RMB 1,515,847,690.53 from RMB 1,616,920,521.54, indicating a reduction in financial obligations[179][180]. - The company's equity attributable to shareholders rose to RMB 1,810,075,763.73 from RMB 1,744,120,502.21, reflecting retained earnings growth[180]. - The cash flow from financing activities showed a net outflow of CNY 249,536,789.45, compared to CNY 20,795,908.50 in the first half of 2018[196]. Investments and R&D - The company plans to continue increasing investments in natural colorants/spices/nutrition and medicinal products in the second half of the year to enhance operational performance in this segment[72]. - The company's R&D expenses amounted to RMB 68,232,441.46, a slight decrease of 2.53% from RMB 70,005,984.59 in the previous year, while R&D project costs increased significantly by 107.80% to RMB 26,095,760.42[70]. - The company has 20 technology platforms, including 5 national-level platforms, enhancing its R&D capabilities and industry technology support[40]. - The company has applied for 298 patents, with 181 patents granted, indicating a strong focus on innovation[43]. - The company has established a research center with advanced laboratories and is collaborating with universities to develop industry-leading products, including key technologies for natural extract crystallization[58]. Market and Product Development - The company remains a leader in the natural plant extract sector, with key products like chili red pigment and lutein ranking first in the industry[31]. - The company has seen rapid growth in products such as cottonseed dephenolized protein and other natural extracts, indicating a strong market expansion[31]. - The company achieved a sales volume of over 3,000 tons of its main product, chili red, representing a year-on-year growth of 31%[54]. - The sales volume of ordinary lutein increased by 35% year-on-year, further expanding market share[54]. - The company has developed and launched 6 types of SC health products, with 10 more in development and 6 registered health food products[54]. Risk Management and Compliance - The company is actively utilizing financial instruments such as export financing and forward foreign exchange contracts to mitigate currency fluctuation risks[5]. - Future growth strategies include thorough market research before project investments to minimize risks associated with overseas operations[5]. - The management has indicated that there are no significant risks that could adversely affect the company's operations in the next reporting period[5]. - The company is committed to maintaining compliance with international standards and certifications to enhance product safety and quality[11]. - The company has established a management system for raised funds to protect investor rights and ensure compliance with regulations[87]. Shareholder and Governance - No cash dividends or stock bonuses will be distributed to shareholders for this reporting period[6]. - The annual shareholders meeting had a participation rate of 35.93%, representing 183,910,738 shares, which is 35.93% of the total voting shares[115]. - The company plans not to distribute cash dividends or issue bonus shares for the half-year period[116]. - The company reported a commitment compliance rate of 100% among its shareholders, with no violations found during the reporting period[119]. - The company has not reported any significant changes in the status of its pledged assets or raised funds management[88]. Social Responsibility and Environmental Impact - The company has increased investments in environmental protection facilities to comply with stricter regulations and reduce production impacts[110]. - The company has actively fulfilled its social responsibilities, including safety management and employee training programs[145]. - The company has expanded its marigold planting area to 130,000 mu, benefiting 29,000 impoverished households[145]. - The company has implemented low nitrogen combustion technology in its natural gas boilers, achieving ultra-low emissions standards[142].

Group 1: Company Overview - Morning Light Biological Technology Group Co., Ltd. is participating in the 2019 Annual Investor Online Reception Day on May 15, 2019 [1] - The company aims to provide comprehensive insights into its situation, development strategy, operational status, and sustainable development [1] Group 2: Event Details - The event will take place from 15:00 to 17:00 on May 15, 2019, organized by the Hebei Regulatory Bureau of the China Securities Regulatory Commission [1] - Investors can participate through the online platform "Panorama Roadshow" [1] Group 3: Engagement and Interaction - Company executives will engage in interactive communication with investors during the event [1] - The company encourages active participation from investors [1]

晨光生物科技集团股份有限公司 2019 年第一季度报告全文 晨光生物科技集团股份有限公司 2019 年第一季度报告 2019-066 2019 年 04 月 1 晨光生物科技集团股份有限公司 2019 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人卢庆国、主管会计工作负责人周静及会计机构负责人(会计主管 人员)宋书军声明：保证季度报告中财务报表的真实、准确、完整。 2 晨光生物科技集团股份有限公司 2019 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |-------|---------|-----------------------------------------------------|------ ...

晨光生物科技集团股份有限公司 2018 年年度报告全文 晨光生物科技集团股份有限公司 2018 年年度报告 2019-022 2019 年 03 月 1 晨光生物科技集团股份有限公司 2018 年年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连 带的法律责任。 公司负责人卢庆国、主管会计工作负责人周静及会计机构负责人(会计主管 人员)宋书军声明：保证年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 | --- | |-----------------------------------------------------------------------------------------| | | | 报告期，公司无新增加的可能对公司下一报告期经营产生不利影响的重大 | | 风险。公司的长期发展目标是 —— 建设世界天然提取物产业基地，要实现该目 | | 标，全球化资源配置是必由之路。但境外的法律、税收、外汇管理、人文环境 | | 以及外交关系 ...

Financial Performance - Operating revenue for the reporting period was ¥847,192,398.50, up by 2.44% compared to the same period last year[8] - Net profit attributable to shareholders of the listed company was ¥33,358,284.51, a decrease of 10.72% year-on-year[8] - Basic earnings per share were ¥0.065, down by 10.96% compared to the same period last year[8] - The weighted average return on net assets was 1.95%, a decrease of 0.41% year-on-year[8] - The total operating revenue for the third quarter was CNY 541.31 million, a decrease of 17% from CNY 652.29 million in the same period last year[74] - The net profit for the third quarter was CNY 32.76 million, down 11.5% from CNY 36.90 million year-over-year[74] - The total comprehensive income for the third quarter was CNY 30.35 million, slightly down from CNY 31.48 million in the same quarter last year[75] - The total profit for the third quarter was CNY 34.94 million, compared to CNY 47.39 million in the same period last year, representing a decrease of 26.3%[74] Assets and Liabilities - Total assets at the end of the reporting period reached ¥2,979,567,594.62, an increase of 3.72% compared to the end of the previous year[8] - Net assets attributable to shareholders of the listed company were ¥1,725,699,664.20, reflecting a growth of 6.20% year-on-year[8] - The total liabilities decreased to CNY 1,088,162,762.92 from CNY 1,127,625,870.63, a decline of 3.5%[70] - The company's non-current assets totaled approximately ¥958.26 million, up from ¥848.52 million, reflecting a growth of 12.9%[66] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥365,000,248.53, down by 39.16% compared to the previous year[8] - Cash received from borrowings increased by 161.67% year-on-year, reflecting the company's growing financing needs[28] - The net cash flow from operating activities for Q3 2018 was CNY 384,135,820.69, a decrease of 6.4% compared to CNY 412,933,412.44 in Q3 2017[90] - The cash and cash equivalents at the end of Q3 2018 were CNY 150,479,058.62, up from CNY 41,311,342.14 at the end of Q3 2017[91] Expenses - Sales expenses rose by 35.36% compared to the same period last year, due to increased product sales and related shipping costs[24] - Interest expenses increased by 33.71% year-on-year, corresponding to a rise in short-term borrowings[25] - The company's financial expenses include interest expenses of CNY 31,967,150.30, which increased from CNY 21,457,010.23 in the previous period[84] - The operating costs for the third quarter were CNY 482.10 million, down from CNY 583.53 million year-over-year, indicating a reduction of 17.4%[77] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 12,032[12] - The company has a profit distribution policy that mandates at least 10% of the annual distributable profit to be distributed in cash[48] - The company aims for cumulative cash distributions over any three consecutive fiscal years to be no less than 30% of the average annual distributable profit for those years[48] - The company will only distribute cash dividends if the distributable profit is positive and cash flow is sufficient to ensure ongoing operations[51] Research and Development - Development expenses surged by 374.89% year-on-year, reflecting increased spending on health food research and development[20] - The company is currently developing 17 projects, including the stevia sugar project aimed at optimizing production processes and improving yield and energy consumption[37] - Research and development expenses for Q3 2018 were CNY 5,471,338.29, down from CNY 6,948,270.13, a decrease of 21.2%[72] Market and Sales Performance - Revenue from natural colorants/spices/nutritional and medicinal products decreased by 7.35% year-on-year, while the gross profit margin decreased by 2.62%[35] - Sales of cottonseed products (self-produced) increased by 34.08% year-on-year, achieving a gross profit of approximately 65.47 million yuan, an increase of about 63.80 million yuan year-on-year[34] - The sales scale of pepper extract increased by over 50% year-on-year, and the sales of lycopene increased by over 500% year-on-year, indicating strong growth potential for these products[34] Investments and Projects - The company plans to establish a wholly-owned subsidiary in Yanchi County, Xinjiang, with an investment of RMB 10 million to enhance its competitiveness in the natural extract industry[41] - The company has completed the installation of a new production line capable of processing 60 tons of ultrafine powder daily at its Kashgar facility[40] - The company is implementing several automation and efficiency improvement projects, including the installation of touch screens for real-time monitoring and control in various workshops[40]